| HLT |
Report |
Q2 2026 currency-neutral systemwide RevPAR growth |
BEAT |
pred ~2.7% vs. cons 2.5% |
MEDIUM |
| HLT |
Report |
Q2 2026 adjusted EBITDA |
IN-LINE |
pred ~$1.040B vs. cons $1.030B |
MEDIUM |
| HLT |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$2.28 vs. cons $2.25 |
MEDIUM |
| HLT |
Guide |
Q3 2026 adjusted EBITDA |
LOWER |
guide ~$1.08B midpoint vs. cons $1.10B (Q3 2026) |
MEDIUM |
| HLT |
Guide |
Currency-neutral systemwide RevPAR growth |
UNCHANGED |
guide ~2.5% midpoint vs. cons 2.5% (FY2026) |
MEDIUM |
| HLT |
Guide |
Adjusted EBITDA |
UNCHANGED |
guide ~$4.05B midpoint vs. cons $4.05B (FY2026) |
MEDIUM |
| HLT |
Guide |
Adjusted EPS |
BETTER |
guide ~$8.98 midpoint vs. cons $8.92 (FY2026) |
MEDIUM |
| HLT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| HLT |
Return |
5-day cumulative residual |
-2.8% (FOLLOW-THROUGH) |
A ~$1.040B Q2 result versus $1.030B consensus is offset by Q3 guidance near $1.08B versus $1.10B consensus. FY2026 EBITDA near $4.05B versus $4.05B consensus implies only ~$2.109B of second-half EBITDA versus the pre-report consensus math of roughly $2.119B, prompting modest out-period estimate cuts despite the EPS beat. |
MEDIUM |